Extended Data Fig. 10: Representation of the effect of low-dose adjuvant epigenetic modifiers on lung metastases in the tumour pulmonary-metastasis models.
From: Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Graphic model showing the inhibition of pulmonary metastases by low-dose AET via its effect on MDSCs. First, low-dose AET can inhibit the trafficking of monocytic and polymorphonuclear MDSCs from the bone marrow to the premetastatic microenvironment by downregulating the expression of CCR2 and CXCR2, respectively. Second, even if MDSCs migrate to the lung, low-dose AET can skew the differentiation of monocytic MDSCs towards an interstitial macrophage-like phenotype in the lung premetastatic microenvironment. Therefore, low-dose AET can disrupt the lung premetastatic microenvironment, ultimately inhibiting pulmonary metastases.
